✦ LIBER ✦

Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

✍ Scribed by Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Plotkin, S. R.; Gerstner, E.; Eichler, A. F.; Drappatz, J.; Hochberg, F. H.; Benner, T.; Louis, D. N.; Cohen, K. S.; Chea, H.; Exarhopoulos, A.; Loeffler, J. S.; Moses, M. A.; Ivy, P.; Sorensen, A. G.; Wen, P. Y.; Jain, R. K.

Book ID: 118169440
Publisher: American Society of Clinical Oncology
Year: 2010
Tongue: English
Weight: 107 KB
Volume: 28
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2009.26.3988

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of SU5416—a small-molecul

Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

✍ Francis J. Giles; Maureen A. Cooper; Lewis Silverman; Judith E. Karp; Jeffrey E. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myeloid leukemia in blastic phase (CML

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Phase I pharmacokinetic study of the vas

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

✍ David A. Reardon; Merrill J. Egorin; Annick Desjardins; James J. Vredenburgh; Ja 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 1 views

An Evaluation of the Drug Interaction Po

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

✍ Goh, B C; Reddy, N J; Dandamudi, U B; Laubscher, K H; Peckham, T; Hodge, J P; Su 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 291 KB

Efficacy and safety of vascular endothel

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

✍ Jae-Lyun Lee; Inkeun Park; Kwonoh Park; Seongjoon Park; Yongcheol Ahn; Jin-Hee A 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 317 KB

A phase I and pharmacokinetic study of d

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB